small molecule

ENSACOVE

ENSARTINIB HYDROCHLORIDE

Loss of exclusivityJune 2037latest FDA-listed patent expiry

CompanyXcovery →View the full company profile on CliffBio

Drug detail

Brand name	ENSACOVE
Active ingredient	ENSARTINIB HYDROCHLORIDE
Strength	EQ 25MG BASE
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	December 2024
Marketing status	RX

Listed patents

Patent	Expires	Type
10899744	June 2037	substance
9126947	November 2031	substance
9296724	June 2029	substance
8551995	February 2029	substance

Regulatory exclusivity

Code	Expires
NCE	December 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Xcovery